223134-14-3

Upstream product

• 299176-17-3 N-(2-nitro-5-chlorophenyl)-N-methylcarbamic acid t-butyl ester 
• 54840-15-2 4-N-tert-butoxycarbonylaminophenol 

Downstream Products

• 223134-16-5 t-butyl N-{5-[4-(t-butoxycarbonyl-n-hexylamino)phenoxy]-2-nitrophenyl}-N-methylcarbamate 
• 223134-15-4 t-butyl N-[2-amino-5-(4-t-butoxycarbonylaminophenoxy)phenyl]-N-methylcarbamate 
• 223133-09-3 t-butyl N-{5-(4-aminophenoxy)-2-[4-(2,4-dioxothiazolidin-5-ylmethyl)phenoxyacetylamino]phenyl}-N-methylcarbamate 
• 1350440-96-8 4-{N-t-butoxycarbonyl-N-[4-[4-amino-3-(N-t-butoxycarbonyl-N-methylamino)phenoxy]phenyl]aminomethyl}-2-propyl-1-[2'-(1-triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-imidazole-5-carboxylic acid ethyl ester 
• 1350440-95-7 4-{N-t-butoxycarbonyl-N-[4-(3-(N-t-butoxycarbonyl-N-methylamino)-4-nitrophenoxy)phenyl]aminomethyl}-2-propyl-1-[2'-(1-triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-imidazole-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE

The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like).

Amine derivative compounds

An amine compound of the formula (I): wherein R1 represents an optionally substituted carbamoyl group, etc., R2 represents a hydrogen atom, etc., R3 represents a C1-C10 alkyl group etc., W1, W2 and W3 are the same or different and each represent a single bond or a C1-C8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a =CH- group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

Substituted fused heterocyclic compound

Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof: wherein R1is a group of the formula (II) or (III): R4is a substituted phenyl or a pyridyl which may have a substituent. R5is hydrogen or the like. R6is hydrogen, a C1-6alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R2is hydrogen or the like. R3is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C1-6alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.